The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
8,499
Sort by:
Interleukin 12 (IL12) - Drugs in Development, 2021
US$ 3,000.00
Interleukin 12 (IL12) - Drugs in Development, 2021 SUMMARY Interleukin 12 (IL12) - Drugs in Development, 2021 provides in depth analysis on Interleukin 12 (IL12) targeted pipeline therapeutics. The re...
April 2021
60 pages
Interleukin 13 (IL13) - Drugs in Development, 2021
US$ 3,000.00
Interleukin 13 (IL13) - Drugs in Development, 2021 SUMMARY Interleukin 13 (IL13) - Drugs in Development, 2021 provides in depth analysis on Interleukin 13 (IL13) targeted pipeline therapeutics. The re...
April 2021
35 pages
Interleukin 15 (IL15) - Drugs in Development, 2021
US$ 3,000.00
Interleukin 15 (IL15) - Drugs in Development, 2021 SUMMARY Interleukin 15 (IL15) - Drugs in Development, 2021 provides in depth analysis on Interleukin 15 (IL15) targeted pipeline therapeutics. The re...
April 2021
60 pages
Interleukin 2 Receptor (IL2R) - Drugs in Development, 2021
US$ 3,000.00
Interleukin 2 Receptor (IL2R) - Drugs in Development, 2021 SUMMARY Interleukin 2 Receptor (IL2R) - Drugs in Development, 2021 provides in depth analysis on Interleukin 2 Receptor (IL2R) targeted pipel...
April 2021
70 pages
Interleukin 23 (IL23) - Drugs in Development, 2021
US$ 3,000.00
Interleukin 23 (IL23) - Drugs in Development, 2021 SUMMARY Interleukin 23 (IL23) - Drugs in Development, 2021 provides in depth analysis on Interleukin 23 (IL23) targeted pipeline therapeutics. The re...
April 2021
35 pages
Interleukin 6 Receptor (IL6R) - Drugs in Development, 2021
US$ 3,000.00
Interleukin 6 Receptor (IL6R) - Drugs in Development, 2021 SUMMARY Interleukin 6 Receptor (IL6R) - Drugs in Development, 2021 provides in depth analysis on Interleukin 6 Receptor (IL6R) targeted pipel...
April 2021
55 pages
Interleukin 7 (IL7) - Drugs in Development, 2021
US$ 3,000.00
Interleukin 7 (IL7) - Drugs in Development, 2021 SUMMARY Interleukin 7 (IL7) - Drugs in Development, 2021 provides in depth analysis on Interleukin 7 (IL7) targeted pipeline therapeutics. The report p...
April 2021
30 pages
Ischemia (Cardiovascular) - Drugs in Development, 2021
US$ 2,000.00
Ischemia (Cardiovascular) - Drugs in Development, 2021 SUMMARY Ischemia (Cardiovascular) - Drugs in Development, 2021 provides an overview of the Ischemia pipeline landscape. The report provides compr...
April 2021
65 pages
